GSK Announces U.S. FDA Approval of Benlysta (Belimumab) For Pediatric Patients With Active Lupus Nephritis
GSK plc (NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving